News

Semler Scientific® Announces BTC and ATM Activity Raised $21.5 million; Purchased Additional 215 BTC; Now Holds 1,273 BTC with BTC Yield of 37.3%

SANTA CLARA, Calif., Nov. 18, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology…

1 year ago

Bestqool Pro Advanced Series: Revolutionizing Red Light Therapy This Black Friday

NEW YORK, Nov. 18, 2024 /PRNewswire/ -- With winter just around the corner, Bestqool is proud to offer a head start…

1 year ago

Webinar to Address Menopause in the Workplace

Program Will Focus on Supporting the Health and Careers of Women in Midlife WASHINGTON, DC / ACCESSWIRE / November 18,…

1 year ago

EW Healthcare Partners Announces Leadership Evolution

Dr. Petri Vainio to become Executive ChairmanDr. Evis Hursever to become CEOScott Barry to become COOMarty Sutter to become Founding…

1 year ago

Hypha Laboratories Announces Completion of Phase 1 of Its State-of-the-Art Facility and Arrival of V5 Working MicroPearls(TM) Prototypes

Advancements Enhance Efficacy in Hypha's Revolutionary Home and Commercial Production UnitsLAS VEGAS, NV / ACCESSWIRE / November 18, 2024 /…

1 year ago

The Hash Corporation Announces Closing of Asset Sale, Name Change, and New Ticker Symbol “STRC.X”

Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Street Capital Inc. (CSE: REZN) (the "Company"), is pleased to announce that…

1 year ago

Mitochondrial Encephalopathy Caused by a New Biallelic Repeat Expansion 

Scientists uncover a new biallelic GGGCC repeat expansion leading to NAXE-related mitochondrial encephalopathy in a three-year-old patient Short tandem DNA…

1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of…

1 year ago

Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024

RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in…

1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Topline results expected in early January 2025CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a…

1 year ago